{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-290447","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2026-06-30T20:01:15+00:00","discovered_at":"2026-06-30T20:02:00.300241+00:00","generated_at":"2026-06-30T20:02:14.877262+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology appoints Scott Garland as Chairman, Michael Listgarten as General Counsel; co-founder resigns","bullets":["Co-founder Corey Goodman resigned as Chairman and board member effective June 29, 2026, for personal reasons.","Scott Garland, independent director since Nov 2022, appointed Chairman of the Board.","Michael Listgarten appointed General Counsel, effective immediately.","Company advancing evorpacept into late-stage development and progressing ALX2004."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-290447","json":"https://secwatch.observer/filing/0001193125-26-290447.json","markdown":"https://secwatch.observer/filing/0001193125-26-290447.md","text":"https://secwatch.observer/filing/0001193125-26-290447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/0001193125-26-290447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/alxo-20260629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:02:14.877262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}